A retrospective in vitro study of the impact of anti-diabetics and cardioselective pharmaceuticals on breast cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 2133-2138

  Szewczyk, M ^a   Richter, C ^b   Briese, V ^a   Richter, Dagmar Ulrike ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Biomedical Physics   (Germany)

Author keywords

Anti diabetics; Beta blockers; Bisoprolol; Breast cancer; BT20; Cell lines; Glitazone; MCF7; Metformin; Propranolol

Indexed keywords

BISOPROLOL; ESTRADIOL; GLITAZONE DERIVATIVE; GLUCOSE; HYDROGEN PEROXIDE; METFORMIN; PROPRANOLOL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DENSITY; CELL PROLIFERATION; CLINICAL PRACTICE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMIDIFIER; HYPERTENSION; IN VITRO STUDY; MICROSCOPY; PH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STRUCTURE ANALYSIS;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; BISOPROLOL; BLOOD GLUCOSE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDROGEN PEROXIDE; HYDROGEN-ION CONCENTRATION; HYPERTENSION; HYPOGLYCEMIC AGENTS; METFORMIN; OXIDATIVE STRESS; PROPRANOLOL; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 84861488690     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tan ST, Itinteang T and Leadbitter P: Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 64: 292-299, 2011.
2. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW and Sood AK: Stress effects on FoOSB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285: 35462-35470, 2010.
3. Wang J, Li J, Sheng X, Zhao H, Cao XD, Wang YQ and Wu GC: Beta-adrenoceptor mediated surgery-induced production of pro-inflammatory cytokines in rat microglia cells. J Neuroimmunol 223: 77-83, 2010.
4. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S and Glaser R: Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66: 10357-10364, 2006. (Pubitemid 44799755)
5. Zimmermann AP, Wiegand S, Werner JA and Eivazi B: Propranolol therapy for infantile haemangiomas: review of the literature. J Pediatr Otorhinolaryngol 74: 338-342, 2010.
6. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A and Ben-Eliyahu S: Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15(7): 2042-2052, 2008.
7. Kato H, Kawaguchi M, Inoue S, Hirai K and Furuya H: The effects of betaadrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats. Anesth Analg 108(1): 288-295, 2009.
8. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF and Bond RA: Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 38(3): 256- 262, 2008.
9. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO and Entschladen F: Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7): 628-638, 2010.
10. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Stabdop J, Ding XZ, Adrian TE and Pour PM: Prevention of pancreatic induction in hamsters by metformin. Gastroenterology 120: 1263-1270, 2001. (Pubitemid 32246678)
11. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10267-10273, 2006.
12. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67(14): 6745-6752, 2007. (Pubitemid 47105521)
13. Zakikhani M, Dowling RJ, Sonenberg N and Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1(5): 369-375, 2008.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956, 1995.
15. Houseknecht KL, Cole BM and Steele PJ: Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22: 1-23, 2002. (Pubitemid 34438654)
16. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H and Auwerx J: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789, 1997. (Pubitemid 27318225)
17. Al-Alem L, Southard RC, Kilgore MW, Curry TE: Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ-independent manner. PLoS One 6(1): e16179, 2011.
18. Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D and Zhang M: Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 22(4): 825-830, 2009.
19. Badino GR, Novelli A, Girardi C and Di Carlo F: Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33(4-5): 255-260, 1996. (Pubitemid 26383686)
20. Natoli C, Sica G, Natoli V, Serra A and Iacobelli S: Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Res Treat 3(1): 23-32, 1983. (Pubitemid 13102083)
21. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9): 1620-1625, 2009.
22. Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 21: 361-379, 2000.
23. Davies KJA: The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. Free Radic Biol Med 29: 323-333, 1999.
24. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004. (Pubitemid 38736063)
25. Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646, 2006. (Pubitemid 44187614)
26. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A and Saavedra E: Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007. (Pubitemid 46333738)